| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRKRA |
| Uniprot No | O75569 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-313aa |
| 氨基酸序列 | MSQSRHRAEA PPLEREDSGT FSLGKMITAK PGKTPIQVLH EYGMKTKNIP VYECERSDVQ IHVPTFTFRV TVGDITCTGE GTSKKLAKHR AAEAAINILK ANASICFAVP DPLMPDPSKQ PKNQLNPIGS LQELAIHHGW RLPEYTLSQE GGPAHKREYT TICRLESFME TGKGASKKQA KRNAAEKFLA KFSNISPENH ISLTNVVGHS LGCTWHSLRN SPGEKINLLK RSLLSIPNTD YIQLLSEIAK EQGFNITYLD IDELSANGQY QCLAELSTSP ITVCHGSGIS CGNAQSDAAH NALQYLKIIA ERK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRKRA重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Recombinant human PACT protein: Cloning, expression, and functional characterization in PKR activation"*
**作者**: Lee, SB., et al.
**摘要**: 该研究报道了人源PRKRA(PACT)重组蛋白的克隆与表达，通过大肠杆菌系统纯化并验证其功能。实验表明重组PACT蛋白能够激活PKR激酶活性，且在细胞应激反应中与双链RNA协同作用，揭示了其结构域对PKR活化的关键影响。
---
2. **文献名称**: *"Structural insights into the interaction of PACT and PKR through recombinant protein co-expression analysis"*
**作者**: Garcia, MA., et al.
**摘要**: 研究利用昆虫细胞系统共表达PRKRA与PKR重组蛋白，解析两者复合物的结构。结果表明，PRKRA的第三结构域(DRBD3)直接结合PKR的激酶结构域，为开发靶向PKR-PACT相互作用的药物提供了结构基础。
---
3. **文献名称**: *"Optimization of PRKRA recombinant protein production in mammalian cells for neurodegenerative disease models"*
**作者**: Chen, L., et al.
**摘要**: 该文优化了哺乳动物细胞中PRKRA重组蛋白的表达条件，证明其在神经细胞中可调控内源性PKR信号通路，并缓解α-突触核蛋白异常聚集导致的细胞毒性，提示其在帕金森病模型中的潜在治疗价值。
---
**备注**：以上文献为示例性质，实际引用时需核实具体作者、年份及期刊信息。若需扩展，可补充关注PRKRA重组蛋白在癌症或病毒感染中的研究(如与干扰素通路的关联)。
**Background of PRKRA Recombinant Protein**
PRKRA (Protein Activator of Protein Kinase R) encodes the interferon-induced double-stranded RNA (dsRNA)-binding protein, PACT, which plays a critical role in cellular stress responses and innate immunity. It interacts with protein kinase R (PKR), a key regulator of translation and apoptosis, to modulate PKR activation under stress conditions such as viral infection, oxidative stress, or DNA damage. Dysregulation of PRKRA/PACT has been linked to neurodegenerative disorders, cancer, and viral pathogenesis, highlighting its importance in maintaining cellular homeostasis.
Recombinant PRKRA protein is engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells*) to produce purified, functional PACT for research and therapeutic applications. Its production often involves tagging (e.g., His-tag, GST-tag) for efficient isolation. Recombinant PRKRA enables mechanistic studies of PKR signaling, stress granule dynamics, and microRNA processing. For example, it helps elucidate how PRKRA mutations (e.g., DYT16 dystonia-linked variants) disrupt PKR binding or stress granule assembly.
Additionally, PRKRA recombinant proteins serve as tools for drug screening, particularly in targeting PKR-related pathways in cancer or neuroinflammation. In virology, they aid in studying viral evasion mechanisms, as some pathogens degrade PACT to suppress antiviral responses. The protein’s role in RNA interference pathways also makes it relevant for developing RNA-based therapies.
Overall, PRKRA recombinant proteins are vital for dissecting its biological functions and exploring therapeutic strategies for diseases linked to PRKRA dysfunction.
×
